Vyant Bio (NASDAQ:VYNT) Cut to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Vyant Bio (NASDAQ:VYNT) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J. “

Separately, HC Wainwright started coverage on Vyant Bio in a research report on Wednesday, October 6th. They set a buy rating and a $5.00 price objective for the company.

Shares of VYNT stock opened at $1.23 on Thursday. The business has a 50 day moving average of $1.74 and a two-hundred day moving average of $2.36. Vyant Bio has a 52 week low of $1.20 and a 52 week high of $17.50.

Vyant Bio (NASDAQ:VYNT) last issued its quarterly earnings data on Thursday, November 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). The business had revenue of $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative return on equity of 28.50% and a negative net margin of 200.79%. During the same period in the previous year, the firm posted ($0.58) earnings per share. On average, analysts predict that Vyant Bio will post 0.75 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Bank of Montreal Can bought a new stake in Vyant Bio during the second quarter worth approximately $37,000. Geode Capital Management LLC raised its holdings in Vyant Bio by 6.9% during the third quarter. Geode Capital Management LLC now owns 188,802 shares of the company’s stock worth $439,000 after purchasing an additional 12,122 shares in the last quarter. Millennium Management LLC bought a new stake in Vyant Bio during the second quarter worth approximately $48,000. Charles Schwab Investment Management Inc. bought a new stake in Vyant Bio during the second quarter worth approximately $49,000. Finally, NorthRock Partners LLC bought a new stake in Vyant Bio during the second quarter worth approximately $70,000. 7.80% of the stock is currently owned by hedge funds and other institutional investors.

Vyant Bio Company Profile

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

See Also: Trading Halts Explained

Get a free copy of the Zacks research report on Vyant Bio (VYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.